Jun. 22 at 7:22 PM
$SLS - Just to clarify: GPs + Keytruda
$MRK achieved a Better Phase 2 Median Overall Survival in Platinum Resistant Ovarian Cancer, 18.4 months, than this drug Elahere 16.4 months, that was bought for
$10.1B...
Just this one Comp -- is worth
$10B
Then you have SLS009 - Phase 2 B AML-MR Data Published at ASH, is Better than Magrolimab P1B AML-MR Data published at ASH that
$GILD Bought for
$4.9B
GPS + Opdivo Phase 1 MOS is 3X longer than Standard of Care for Mesothelioma Patients.
Dr. Cohen of
$MRK co-authored this paper stating GPs will work even better in a Macroscopic state --- Merck has been waiting, just like all of us, for ever, for this extended Near Miraculous AML CR2 Phase 3 Maintenance Trial to Complete - before paying the MAX PRICE.
